Vitamin D receptor activation and survival in chronic kidney disease. (Q37089710)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18288097%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

review article

1 reference

title

Vitamin D receptor activation and survival in chronic kidney disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18288097%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

0 references

0 references

Kamyar Kalantar-Zadeh

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18288097%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

C P Kovesdy

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18288097%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

language of work or name

English

0 references

publication date

20 February 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18288097%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18288097%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18288097%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18288097%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

1355-1363

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18288097%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/ki.2008.35

3 January 2020

exact match

0 references

cites work

Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Skeletal Resistance to Endogenous Parathyroid Hormone in Patients with Early Renal Failure. A Possible Cause for Secondary Hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

FGF23: its role in renal bone disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Impact of kidney bone disease and its management on survival of patients on dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Activated injectable vitamin D and hemodialysis survival: a historical cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Mortality risk among hemodialysis patients receiving different vitamin D analogs

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Glucose intolerance is associated with altered calcium homeostasis: a possible link between increased serum calcium concentration and cardiovascular disease mortality

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Effect of parathyroid hormone on erythropoiesis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Vitamin D levels and early mortality among incident hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Active serum vitamin D levels are inversely correlated with coronary calcification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

1,25-dihydroxyvitamin D3 inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

An overview of relations among causal modelling methods

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Marginal structural models and causal inference in epidemiology

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Serum phosphate levels and mortality risk among people with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Association of Disorders in Mineral Metabolism with Progression of Chronic Kidney Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Vitamin D analogue-specific recruitment of vitamin D receptor coactivators

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

New vitamin D analogs

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Differential effects of vitamin D analogs on vascular calcification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Differential effects of vitamin D receptor activators on vascular calcification in uremic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

The use of 1,25-dihydroxyvitamin D3 in early renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Antiproteinuric effect of oral paricalcitol in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Interleukin-6 induced suppression of bovine parathyroid hormone secretion

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Inhibition of PTH secretion by interleukin-1 beta in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium-sensing receptor mRNA.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Hyperparathyroidism and 1,25-Dihydroxyvitamin D Deficiency in Mild, Moderate, and Severe Renal Failure*

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Recovery of impaired K+ channels in mesenteric arteries from spontaneously hypertensive rats by prolonged treatment with cholecalciferol

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Effect of cholecalciferol treatment on the relaxant responses of spontaneously hypertensive rat arteries to acetylcholine

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

The effect of 1α(OH)D3 and 1α,25(OH)2D3 on the bone in patients with renal osteodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Calcium-sensing receptor regulation of renal mineral ion transport

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.35

7 January 2021